We need to know the risk of your breast cancer recurring
If you have been diagnosed with breast cancer (ER+ or ER- lymph node negative patients below 61 years) MammaPrint helps your physician make the best-informed decisions to determine your optimal treatment regime.
If there is a low risk of your cancer recurring, you may be able to avoid adjuvant therapy, and the toxicity and other side-effects often associated with such treatment.
Using the latest molecular diagnostic tools, MammaPrint provides a clear risk assessment – delivering your test results within 10 working days.
MammaPrint assesses clearly the individual risk of breast cancer recurrence
MammaPrint provides valuable information to decide on the right treatment
MammaPrint is cleared by the FDA and has been proven in more than 12,000 tests
MammaPrint means no additional invasive procedures
MammaPrint Patients Video
This video shows general information about the MammaPrint technology and its advantages for patients.
Services & Products 
